Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
11 December 2020Website:
http://www.abcellera.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:49:28 GMTDividend
Analysts recommendations
Institutional Ownership
ABCL Latest News
AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summer.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time) Live audio webcasts of each presentation may be accesse.
AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript
Although the revenue and EPS for AbCellera Biologics Inc. (ABCL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here is how AbCellera Biologics Inc. (ABCL) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.
AbCellera Biologics is a biotech company using AI-powered platforms to discover and analyze target-specific antibodies. The company emphasizes partnerships to expedite drug development and has two drugs set for IND approval in 2025. AbCellera has a strong financial position and is trading at a relatively low cash multiple, making it an attractive investment in biotech.
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Participants Allison Bratzel - Piper Sandler Robyn Karnauskas - Truist Andrea Tan - Goldman Sachs Stephen Willey - Stifel Puneet Souda - Leerink Partners Steven Mah - Cowen Malcolm Hoffman - BMO Operator Good afternoon, and welcome to AbCellera's Third Quarter 2023 Business Update Conference Call. My name is Kate, and I will facilitate the audio portion of today's interactive broadcast.
GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023.
- 1(current)
What type of business is AbCellera Biologics?
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
What sector is AbCellera Biologics in?
AbCellera Biologics is in the Healthcare sector
What industry is AbCellera Biologics in?
AbCellera Biologics is in the Biotechnology industry
What country is AbCellera Biologics from?
AbCellera Biologics is headquartered in Canada
When did AbCellera Biologics go public?
AbCellera Biologics initial public offering (IPO) was on 11 December 2020
What is AbCellera Biologics website?
https://www.abcellera.com
Is AbCellera Biologics in the S&P 500?
No, AbCellera Biologics is not included in the S&P 500 index
Is AbCellera Biologics in the NASDAQ 100?
No, AbCellera Biologics is not included in the NASDAQ 100 index
Is AbCellera Biologics in the Dow Jones?
No, AbCellera Biologics is not included in the Dow Jones index
When does AbCellera Biologics report earnings?
The next expected earnings date for AbCellera Biologics is 02 August 2024